157 filings
Page 2 of 8
6-K
n8s3ma6 koj4f03obk
26 Sep 23
Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32 Million
6:05am
6-K
147p35mc
21 Sep 23
Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates
10:52am
6-K
0cy2nto0l
7 Sep 23
Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate
5:00pm
6-K
3vpu9kl0hq7 63
1 Sep 23
Valneva to Participate in Investor Conferences in the United States and Europe in September 2023
5:00pm
6-K
wdqc6n1d
29 Aug 23
Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate
8:00am
6-K
n510fkw6t
17 Aug 23
Valneva Announces Extension of Existing Loan Agreement
6:05am
6-K
edgz3yh7qidbyvbn6t
14 Aug 23
Valneva Announces PDUFA Date Extension for Chikungunya Virus Vaccine Candidate
1:00pm
UPLOAD
i7myz byfaspclp0
14 Aug 23
Letter from SEC
12:00am
20-F/A
35j 4fuiqq
10 Aug 23
Annual report (foreign) (amended)
5:35pm
CORRESP
vusn4ugqdr
10 Aug 23
Correspondence with SEC
12:00am
UPLOAD
i7l5miz2wc qlqg0n
3 Aug 23
Letter from SEC
12:00am
6-K
r67nte7j47m g13
22 Jun 23
Valneva Announces Successful Outcome of its AGM and the Appointment of Pfizer’s Former Vaccine R&D Head to its Supervisory Board
5:00pm
6-K
1gin5q6
14 Jun 23
Valneva Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in The Lancet
12:00pm
6-K
pyxnce x7u
31 May 23
Current report (foreign)
4:30pm
6-K
o2kot5sy qexp
4 May 23
Current report (foreign)
11:38am
6-K
hhjlt
31 Mar 23
Current report (foreign)
4:05pm
6-K
0rlq9 mzkwn3d
23 Mar 23
Valneva Reports Full Year 2022 Results and Provides Corporate Updates
3:09pm
6-K
vvk lmdj1j
2 Mar 23
Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001
5:30pm
6-K
9ad 3lljrei0
21 Feb 23
Current report (foreign)
6:10am